Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Deloitte
Merck
Express Scripts
Medtronic
Queensland Health
Baxter
McKesson
Fuji
Dow

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,501,228

« Back to Dashboard

Which drugs does patent 8,501,228 protect, and when does it expire?

Patent 8,501,228 protects DUEXIS and is included in one NDA.

This patent has twenty-two patent family members in fourteen countries.
Summary for Patent: 8,501,228
Title:Stable compositions of famotidine and ibuprofen
Abstract: Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.
Inventor(s): Xu; Jerry (Hunt Valley, MD), Tidmarsh; George F. (Portola Valley, CA)
Assignee: Horizon Pharma USA, Inc. (Deerfield, IL)
Application Number:13/620,141
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 8,501,228

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Horizon Pharma DUEXIS famotidine; ibuprofen TABLET;ORAL 022519-001 Apr 23, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,501,228

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,449,910 Stable compositions of famotidine and ibuprofen ➤ Subscribe
8,067,033 Stable compositions of famotidine and ibuprofen ➤ Subscribe
8,067,451 Methods and medicaments for administration of ibuprofen ➤ Subscribe
8,318,202 Stable compositions of famotidine and ibuprofen ➤ Subscribe
8,309,127 Stable compositions of famotidine and ibuprofen ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,501,228

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 539747 ➤ Subscribe
Australia 2006269894 ➤ Subscribe
Australia 2007275360 ➤ Subscribe
Brazil PI0714937 ➤ Subscribe
Canada 2615496 ➤ Subscribe
Canada 2657928 ➤ Subscribe
China 101257800 ➤ Subscribe
China 101516368 ➤ Subscribe
Denmark 2043637 ➤ Subscribe
European Patent Office 1919288 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Merck
Express Scripts
Dow
Novartis
Johnson and Johnson
UBS
US Department of Justice
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot